Davis Polk advised Centogene N.V. on the deal.
Centogene N.V. closed a $56 million initial public offering of 4,000,000 of its common shares.
In addition, Centogene has granted the underwriters a 30-day option to purchase up to an additional 600,000 common shares. The common shares are listed on the Nasdaq Global Market under the symbol “CNTG.”
SVB Leerink and Evercore ISI are acting as joint book-running managers for the offering, with Baird and BTIG acting as co-managers.
Based in Rostock, Germany, Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company’s goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using their knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers.
The Davis Polk corporate team included partners Leo Borchardt (Picture) and Richard D. Truesdell Jr. and associates Andrew Rowe and Grace M. Cao. The tax team included partner Michael Mollerus and associate Tomislava Dragicevic. The intellectual property and technology team included partner David R. Bauer and associate Jay Frankel. The executive compensation team included partner Veronica M. Wissel and associate Justin Alexander Kasprisin.
Involved fees earner: David Bauer – Davis Polk & Wardwell; Leo Borchardt – Davis Polk & Wardwell; Grace Cao – Davis Polk & Wardwell; Tomislava Dragicevic – Davis Polk & Wardwell; Jay Frankel – Davis Polk & Wardwell; Justin Alexander Kasprisin – Davis Polk & Wardwell; Michael Mollerus – Davis Polk & Wardwell; Andrew Rowe – Davis Polk & Wardwell; Richard Truesdell Jr. – Davis Polk & Wardwell; Veronica Wissel – Davis Polk & Wardwell;
Law Firms: Davis Polk & Wardwell;